Show results for
Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Stem Cell Ideas Into Effective Therapies Equipment Supplied In Usa
14 equipment items found
by:National Resilience, Inc. based inSan Diego, CALIFORNIA (USA)
Innovators in immunotherapy, stem cell therapy, and regenerative medicine will find like-minded champions at ...
Manufactured by:Vetherapy based inSan Francisco, CALIFORNIA (USA)
Our proprietary stem cell therapies are optimized for inflammatory, auto-immune and neurologic disorders in pets and can be delivered ready to inject anywhere in the world. We provide stem cells for cats, dogs and ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Stem cells, including inducible pluripotent stem cells, mesenchymal stem cells (MSCs) and other primary pluripotent cells, hold the potential to treat a variety of diseases. We are currently focusing on developing an allogeneic decidua stromal cells (DSCs)-based platform to treat severe immune-mediated diseases. Our pre-clinical and clinical data suggest that the immunomodulatory activity of DSCs ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
The HERV-E target is one of the quiescent Human Endogenous Retro-Virus (HERV) sequences that are turned on during tumor development. Its expression in renal cell carcinoma (RCC) is highly selective, with no transcripts detected in any normal tissues. It is expressed in 85% of clear cell RCC (ccRCC). The TCR molecule was identified in a responding patient, following allogeneic stem cell therapy. ...
Manufactured by:Stemedica Cell Technologies, Inc. based inSan Diego, CALIFORNIA (USA)
There are two types of cells currently used for investigating progenitor cell therapies for degenerative diseases: autologous and allogeneic. Autologous progenitor cells are derived from the patient being treated. They are retrieved surgically, expanded, and transplanted back into the same patient. Allogeneic progenitor cells are derived from healthy volunteers or organ donations. These cells ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
Morquio B, also known as Mucopolysaccharidosis type IV (MPS IV), is a progressive disease mostly impacting the skeleton, caused by mutations in GLB1, the gene that encodes the beta-galactosidase (GLB) enzyme. These mutations result in the misfolding and subsequent dysfunction of GLB, which leads to the toxic substrate accumulation of keratan sulfate in organs and tissues. Very limited and ...
by:Gain Therapeutics, Inc. based inBethesda, MARYLAND (USA)
GM1 Gangliosidosis is a hereditary, progressive disease mostly impacting neurons in the brain and spinal cord, caused by mutations in GLB1, the gene that encodes the beta-galactosidase (GLB) enzyme. These mutations result in the misfolding and subsequent dysfunction of GLB, which leads to the toxic substrate accumulation of GM1 ganglioside in organs and tissues. Very limited and investigational ...
Manufactured by:KORU Medical Systems based inMahwah, NEW JERSEY (USA)
Primary Immunodeficiency Diseases (PIDD) are a group of over 350 chronic disorders resulting from defects in the body's immune system that are caused by hereditary or genetic defects. PIDD patients have an increased susceptibility to infection due to their defective immune response, enduring recurrent health problems and often developing serious illnesses. With proper medical care, many patients ...
by:Aegle Therapeutics based inWoburn, MASSACHUSETTS (USA)
Aegle’s founder Dr. Evangelos Badiavas and his team have spent decades researching clinical applications of mesenchymal stem cells (“MSCs”) in severe dermatological disorders, including conducting clinical trials in burns and wounds under multiple INDs. In these trials, patients experienced accelerated healing, little to no scarring, total wound closure and tissue regeneration. ...
by:Thermo Fisher Scientific, LIMS & Laboratory Software based inPhiladelphia, PENNSYLVANIA (USA)
Cell Therapy Systems—a proven choice for clinical cell therapy manufacturing. As you move from basic cell therapy research to the clinic, high-quality GMP-grade cell therapy ancillary materials and proper documentation are essential to getting it right the first time. Cell Therapy Systems (CTS) products provide a proven choice for clinical stem cell therapy and immunotherapy research and ...
Manufactured by:U.S. Stem Cell, Inc. (USRM) based inSunrise, FLORIDA (USA)
U.S. Stem Cell’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack. The procedure involves a physician removing a small amount of muscle from the patient’s thigh. From this muscle specimen, muscle stem cells (also called myoblasts) ...
by:VetStem Biopharma based inPoway, CALIFORNIA (USA)
The StemInsure® process can be performed before your dog has arthritis or an injury so that when your dog needs stem cells, no additional fat collection surgery is ...
Manufactured by:Ocugen, Inc. based inMalvern, PENNSYLVANIA (USA)
OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases (“IRDs”). It consists of a functional copy of a nuclear hormone receptor (“NHR”) gene, NR2E3, delivered to target cells in the retina using an adeno-associated ...
Manufactured by:Biocardia, Inc. based inSunnyvale, CALIFORNIA (USA)
The investigational CardiAMP™ Cell Therapy is designed to be a comprehensive biotherapeutic heart failure solution, incorporating: a proprietary molecular diagnostic to characterize the potency of a patient’s own bone marrow cells and determine if they are an optimal candidate for therapy. a point of care processing platform to prepare cells at the patient’s bedside. an ...